t. Jude Children’s Research Hospital scientists have mapped the structural details of how p53 attaches to its regulatory protein, called BCL-xL, in the cell. The protein p53 is a key activator of the cell's protective machinery against genetic damage, such as the mutations that drive cancer cells' explosive growth.
St. Jude Children’s Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging. The findings appear in the current issue of the scientific journal Nature Neuroscience.
Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children’s Research Hospital.
Brenda Schulman, Ph.D., of St. Jude Children’s Research Hospital, has been elected to the National Academy of Sciences.
The St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients. The research appears today as an advance online publication in the scientific journal Nature Genetics.
The St. Jude Children’s Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The research was published today online ahead of print in the journal Cell Reports.
The quest to improve survival of children with a high-risk brain tumor has led St. Jude Children’s Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other cancers. The study was published today online ahead of print in the journal Cancer Cell.
Adult survivors of childhood cancer face significant health problems as they age and are five times more likely than their siblings to develop new cancers, heart and other serious health conditions beyond the age of 35, according to the latest findings from the world’s largest study of childhood cancer survivors. St. Jude Children’s Research Hospital led the research, results of which appear in the March 17 issue of the Journal of Clinical Oncology.
The St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The research appears February 19 as an advanced online publication in the scientific journal Nature.
St. Jude Children’s Research Hospital scientists have identified a signature immune response that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes. The findings also help explain why infants and toddlers are at elevated risk for flu complications. The research appears in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine.
St. Jude Children’s Research Hospital scientists led a study showing that mutations in a gene responsible for amyotrophic lateral sclerosis (ALS) disrupt the RNA transport system in nerve cells. The findings appear in the current issue of the scientific journal Neuron and offer a new focus for efforts to develop effective treatments.
St. Jude Children’s Research Hospital scientists have discovered a promising new class of antibiotics that could aid efforts to overcome drug-resistance in tuberculosis, a global killer.
A St. Jude Children’s Research Hospital study found that despite being diagnosed with life-threatening illnesses, childhood cancer patients are no more likely than their healthy peers to develop post-traumatic stress disorder.
St. Jude Children’s Research Hospital has been recognized for the fourth consecutive year as one of FORTUNE magazine’s “100 Best Companies to Work For.” The hospital ranked 30 up 22 places from last year. St. Jude employees give particularly high ratings to their pride in working for the organization and ability to make a difference.
At St. Jude Children’s Research Hospital, the centuries-old practice of yoga is combined with nutrition education to help young cancer patients manage their disease today and lay the foundation for a healthy future. The program was created by the departments of Clinical Nutrition and Rehabilitation Services.
St. Jude Children’s Research Hospital scientists have identified a protein complex that is essential for jumpstarting the immune response during the critical first 24 hours of an infection. The research appears in the current issue of the scientific journal Immunity.
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.
St. Jude Children’s Research Hospital scientists have identified an enzyme that can halt or possibly even reverse the build-up of toxic protein fragments known as plaques in the brains of mice with Alzheimer’s disease. The research appeared in a recent edition of the scientific journal Nature Communications.
St. Jude Children’s Research Hospital scientists have evidence that descendants of the H2N2 avian influenza A virus that killed millions worldwide in the 1950s still pose a threat to human health, particularly to those under 50. The research has been published in an advance online edition of the Journal of Virology.
Young adults who survived childhood cancer are more likely than their peers to be frail, according to a St. Jude Children’s Research Hospital study, which reported the condition is more common among female survivors than women decades older.
Combining the drug gemtuzumab ozogamicin (GO) with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia (AML), according to a study led by St. Jude Children’s Research Hospital.
James R. Downing, M.D., scientific director, deputy director and executive vice president at St. Jude Children’s Research Hospital, has been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences. Downing’s election brings the number of IOM members from St. Jude to six. St. Jude has one of the highest numbers of IOM members among U.S. children’s hospitals.
Research led by St. Jude Children’s Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome.
A study led by St. Jude Children’s Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.
St. Jude Children’s Research Hospital has named Robyn Diaz, J.D., as its chief legal officer and senior vice president. With 10 years of health law experience and 15 years of experience in the health care industry, Diaz joined the hospital’s Office of General Counsel as associate general counsel in August 2010 and was promoted to deputy general counsel in May 2012.
For childhood cancer survivors, risk factors associated with lifestyle, particularly hypertension, dramatically increase the likelihood of developing serious heart problems as adults, according to a national study led by St. Jude Children’s Research Hospital.
Charles J. Sherr, M.D., Ph.D., chair of the St. Jude Children’s Research Hospital Department of Tumor Cell Biology and a Howard Hughes Medical Institute Investigator, has been selected to receive the 2013 Prize for Scientific Excellence in Medicine by the American-Italian Cancer Foundation.
St. Jude Children’s Research Hospital officials have named Larry Kun, M.D., an internationally recognized radiation oncologist, as clinical director and executive vice president. Kun will guide all aspects of clinical care and oversee clinical operations, clinical effectiveness practices and patient care quality programs for the 7,800 patients who are treated or receive post-treatment care at St. Jude each year. His responsibilities include developing patient care policies, managing physicians—including consulting physicians and other clinical staff—as well as planning and managing clinical space and systems. Kun has served as chair of the St. Jude Department of Radiological Sciences and will remain in that position.
The risk of death following bone marrow transplantation can be reduced about 60 percent using a new technique to identify bone marrow donors who make the most potent cancer-fighting immune cells, according to research from St. Jude Children’s Research Hospital.
St. Jude Children’s Research Hospital today announced that its director and CEO, Dr. William E. Evans, has decided to retire from his executive post in July of 2014. Evans has been with the organization for more than 40 years and has served as CEO for the past 10 years.
Researchers have discovered the first inherited gene mutation linked exclusively to acute lymphoblastic leukemia (ALL) occurring in multiple relatives in individual families.
September marks Childhood Cancer Awareness Month, a time to highlight efforts to reduce the disease’s toll on children. At St. Jude, the past year has brought advances in understanding and treating childhood cancer, particularly in the areas of genomics and survivorship.
St. Jude Children’s Research Hospital will host a webcast about the late-effects of childhood cancer and its treatment Saturday, September 7, at 9 a.m. CST.
drug proven effective for treatment of adults and children with sickle cell anemia reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to an analysis led by St. Jude Children’s Research Hospital.
St. Jude Children’s Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing tumor cells.
Researchers have tied mutations in a gene that causes amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders to the toxic buildup of certain proteins and related molecules in cells, including neurons.
St. Jude Children’s Research Hospital scientists have discovered a way to target the immune system to shrink or eliminate tumors in mice without causing autoimmune problems.
St. Jude Children’s Research Hospital has earmarked $5.5 million for the creation of the Donald Pinkel Endowed Chair of Pediatric Cancer Treatment, which has been granted by the ALSAC and St. Jude Boards of Directors and Governors.
St. Jude Children’s Research Hospital scientists have discovered that a protein used by cancer cells to evade death also plays a vital role in heart health.
St. Jude Children’s Research Hospital study challenges prior understanding of the process regulating specialized T cells that are essential for a balanced immune system
St. Jude Children’s Research Hospital has found that childhood cancer survivors overwhelmingly experience a significant amount of undiagnosed, serious disease through their adult years, establishing the importance of proactive, life-long clinical health screenings for this growing high-risk population.
Changes in an epigenetic mechanism that turns expression of genes on and off may be as important as genetic alterations in causing pediatric acute lymphoblastic leukemia (ALL), according to a study led by scientists at St. Jude Children’s Research Hospital and published in the June 10 online edition of the Journal of Clinical Investigation.
Michael Dyer, Ph.D., a scientist at St. Jude Children's Research Hospital, has been selected as a Howard Hughes Medical Institute (HHMI) investigator.
The St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project advances understanding of genetic defects underlying childhood low-grade gliomas and identifies promising new drug therapies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right